17β-Hydroxysteroid Dehydrogenase Type 14 Is a Predictive Marker for Tamoxifen Response in Oestrogen Receptor Positive Breast Cancer
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: 17β-Hydroxysteroid dehydrogenases (17βHSDs) are important enzymes regulating the pool of bioactive steroids in the breast. The current study was undertaken in order to evaluate implications of 17βHSD14 in breast cancer, measuring 17βHSD14 protein expression in breast tumours. METHODS: An antibody targeting the 17βHSD14 antigen was generated and validated using HSD17B14-transfected cells and a peptide-neutralising assay. Tissue microarrays with tumours from 912 post-menopausal women diagnosed with lymph node-negative breast cancer, and randomised to adjuvant tamoxifen or no endocrine treatment, were analysed for 17βHSD14 protein expression with immunohistochemistry. RESULTS: Results were obtained from 847 tumours. Patients with oestrogen positive tumours with high 17βHSD14 expression had fewer local recurrences when treated with tamoxifen (HR 0.38; 95% C.I. 0.19-0.77, p = 0.007) compared to patients with lower tumoural 17βHSD14 expression, for whom tamoxifen did not reduce the number of local recurrences (HR 1.19; 95% C.I. 0.54-2.59; p = 0.66). No prognostic importance of 17βHSD14 was seen for systemically untreated patients. CONCLUSIONS: Using a highly specific validated antibody for immunohistochemical analysis of a large number of breast tumours, we have shown that tumoural expression levels of 17βHSD14 can predict the outcome of adjuvant tamoxifen treatment in terms of local recurrence-free survival in patients with lymph node-negative ER+ breast cancer. The results need be verified to confirm any clinical relevance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HSD17B14 also has oxidative 17β-HSD activity and has been immunolocalised to endometrial glandular epithelial cells [46] although relative efficiency for oxidation of E2 or T was much lower than that of HSD17B2 in cell metabolism assays.”
From Endometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders (2018) · cites this paper as [46]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075 · cited 1×
“Although the overall benefit from tamoxifen in reducing the risk of breast cancer relapse is clear, with clinical trials demonstrating an approximate 50% reduction in relapse for patients with ER+ tumours [10,15], a subset of patients fail to respond to the drug, either due to acquired resistance or to an intrinsic in…”
The Endogenous Hormones and Breast Cancer Collaborative Group (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.8.606 · Cited by 1,793 · cited 1×
“Although ovarian oestrogen production ceases at menopause, the supply of oestrogens is maintained through local production from aromatisation of androgens [12], and a high postmenopausal plasma oestradiol level is associated with a subsequent risk of developing breast cancer [13].”
van Landeghem, A. A. J., Poortman, J., Nabuurs, M., & Thijssen, J. H. H. (1985) · PubMed · Cited by 448
An ADIOL-ERβ-CtBP Transrepression Pathway Negatively Regulates Microglia-Mediated Inflammation
Saijo, K., Collier, J. G., Li, A. C., Katzenellenbogen, J. A., & Glass, C. K. (2011) · Cell · doi:10.1016/j.cell.2011.03.050 · Cited by 290 · cited 1×
“In a recent publication 17bHSD14 is shown to act immunomodulatory, affecting the levels of 5-androstenediol which in turn is shown to be a significant inducer of anti-inflammatory responses mediated by ERb in the central nervous system [18].”
DHEA and peripheral androgen and estrogen formation: intracrinology
LABRIE, F., BÉLANGER, A., SIMARD, J., LUU‐THE, V., & LABRIE, C. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb17369.x · Cited by 280 · cited 1×
“Peripheral intracrine sex steroid synthesis from adrenally derived steroid precursors in target organs is an ongoing event throughout life which becomes exceedingly important when the gonadal sources of sex steroids cease, as is the case for oestrogen synthesis in women after menopause [1].”
Gunnarsson, C., Olsson, B., & Stål, O. (2001) · PubMed · Cited by 123
Self-citationDay, J. M., Tutill, H. J., Purohit, A., & Reed, M. J. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0042 · Cited by 122
17β-Hydroxysteroid Dehydrogenase Type 1 Is an Independent Prognostic Marker in Breast Cancer
Oduwole, O. O., Li, Y., Isomaa, V. V., Mäntyniemi, A., Pulkka, A. E., Soini, Y., & Vihko, P. T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0446 · Cited by 117
Rutqvist, L. E., Johansson, H., & (on behalf of the Stockholm Breast Cancer Study Group) (2006) · Acta Oncologica · doi:10.1080/02841860601034834 · Cited by 114 · cited 2×
“The tumour material in this study was derived from a randomised tamoxifen trial conducted in Stockholm, Sweden 1976–1990 which comprised 1780 low risk breast cancer patients [10].”
Lønning, P. E., Dowsett, M., & Powles, T. (1990) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(90)90241-j · Cited by 110 · cited 1×
“Although ovarian oestrogen production ceases at menopause, the supply of oestrogens is maintained through local production from aromatisation of androgens [12], and a high postmenopausal plasma oestradiol level is associated with a subsequent risk of developing breast cancer [13].”
Lukacik, P., Keller, B., Bunkoczi, G., Kavanagh, K., Hwa Lee, W., Adamski, J., & Oppermann, U. (2007) · Biochemical Journal · doi:10.1042/bj20061319 · Cited by 99 · cited 1×
“We and others have shown that the enzyme oxidises potent oestradiol into less bioactive oestrone [7,8].”
Amplification of HSD17B1 and ERBB2 in primary breast cancer
Gunnarsson, C., Waltersson, M. A., Kirschner, K., Olsson, B., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2003) · Oncogene · doi:10.1038/sj.onc.1206078 · Cited by 89 · cited 1×
“Expression levels and activity of 17bHSD1, which reduces oestrone to oestradiol, is thought to be of relevance for the local elevation of oestradiol levels measured in tumours compared to plasma, observed in breast cancer, and indeed intratumoural levels of this enzyme have been shown to be of prognostic importance in…”
Self-citationJansson, A. K., Gunnarsson, C., Cohen, M., Sivik, T., & Stål, O. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1448 · Cited by 71
Self-citationKhoshnoud, M. R., Löfdahl, B., Fohlin, H., Fornander, T., Stål, O., Skoog, L. K., Bergh, J. C. S., & Nordenskjöld, B. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1202-7 · Cited by 59 · cited 1×
“Comparative analysis of the same tumour material has shown immunohistochemistry and cytosol analysis for the determination of ER-status to be equally effective at predicting longterm effect of adjuvant tamoxifen [11].”
Self-citationAmplification of HSD17B1 has prognostic significance in postmenopausal breast cancer
Gunnarsson, C., Jerevall, P.-L., Hammar, K., Olsson, B., Nordenskjöld, B. A., Jansson, A., & Stål, O. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9579-7 · Cited by 40 · cited 1×
“Expression levels and activity of 17bHSD1, which reduces oestrone to oestradiol, is thought to be of relevance for the local elevation of oestradiol levels measured in tumours compared to plasma, observed in breast cancer, and indeed intratumoural levels of this enzyme have been shown to be of prognostic importance in…”
Self-citationIino, Y., Wolf, D., Langan-Fahey, S. M., Johnson, D. A., Ricchio, M. E., Thompson, M., & Jordan, V. C. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.457 · Cited by 39 · cited 1×
“This scenario has been described in a murine model by Iino et al who demonstrated that, although tamoxifen inhibited the growth of MCF-7 tumours in athymic mice, the tamoxifen inhibitory effect on tumour growth could be partially reversed by increased oestradiol levels [17].”
Jansson, A., Delander, L., Gunnarsson, C., Fornander, T., Skoog, L. K., Nordenskjöld, B. A., & Stål, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2599 · Cited by 36 · cited 4×
“Interestingly, in that study, high tumoural expression of 17bHSD2 as compared with 17bHSD1 was significantly beneficial for tamoxifen response when considering distant recurrence and breast cancer survival as endpoint, whereas it was not significant when considering local recurrence as endpoint [9].”
InfluentialSelf-citationProgestins in the menopause in healthy women and breast cancer patients
Pasqualini, J. R. (2009) · Maturitas · doi:10.1016/j.maturitas.2008.12.008 · Cited by 12 · cited 1×
“Although the overall benefit from tamoxifen in reducing the risk of breast cancer relapse is clear, with clinical trials demonstrating an approximate 50% reduction in relapse for patients with ER+ tumours [10,15], a subset of patients fail to respond to the drug, either due to acquired resistance or to an intrinsic in…”
Cited by
Hilborn, E., Stål, O., & Jansson, A. (2017) · Oncotarget · doi:10.18632/oncotarget.15547 · Cited by 119
Self-citationEndometrial Intracrinology: Oestrogens, Androgens and Endometrial Disorders
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103276 · Cited by 70
“HSD17B14 also has oxidative 17β-HSD activity and has been immunolocalised to endometrial glandular epithelial cells [46] although relative efficiency for oxidation of E2 or T was much lower than”
BackgroundAndrogen receptor: A promising therapeutic target in breast cancer
Vasiliou, S. K., & Diamandis, E. P. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1575643 · Cited by 55
Subcellular localization and membrane topology of 17β-hydroxysteroid dehydrogenases
Tsachaki, M., & Odermatt, A. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.07.003 · Cited by 36
Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism
Diot, C., García-González, A. P., Vieira, A. F. C., Walker, M. D., Honeywell, M. E., Doyle, H., Ponomarova, O., Rivera, Y., Na, H., Zhang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33299-5 · Cited by 28
Metadata
- Authors
- Sivik, T., Gunnarsson, C., Fornander, T., Nordenskjöld, B., Skoog, L., Stål, O., & Jansson, A.
- Affiliations
- Linköping University (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Sivik, Tove
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-07-06
- Volume
- 7
- Issue
- 7
- Pages
- e40568
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3391289
- OpenAlex
- W1974154390
- Cited by
- 17
- References
- 19
- Citations by year
- 2026: 1 · 2024: 1 · 2022: 2 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 3
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DiVA (Linkoping University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Insamlingsstiftelsen Cancer- och Allergifonden
- Cancerfonden
- Vetenskapsrådet (K2008-54X-20639-01-3)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- tamoxifen response, estrogen receptor-positive breast cancer, node-negative breast cancer, local recurrence, predictive biomarkers, adjuvant endocrine therapy, steroid metabolism, antibody validation
- MeSH terms
- Breast Neoplasms, Female, Humans, Neoplasm Recurrence, Local, Prognosis, Receptors, Estrogen, Tamoxifen, 17-Hydroxysteroid Dehydrogenases, Biomarkers, Treatment Outcome, Antineoplastic Agents, Hormonal, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.